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Abstract
Purinergic signaling is a sophisticated system of elements in which ATP and
related molecules function as intercellular messengers. When ATP is released into
the extracellular space, it activates specific receptors that belong to the P2 family. In
parallel, ectonucleotidases transform ATP in its dephosphorylated metabolites
including adenosine, which stimulates P1 receptors. The activity of both receptors
influences various cellular processes. Moreover, metabolic conditions are
concatenated with purine signaling to conform a dynamic and continuous informa-
tional network. The role of purinergic signaling in ovarian cells has been investi-
gated, for instance, it is known that cells conforming the follicle express functional
receptors that modulate basic cellular process such as proliferation, induction of
apoptotic cell death, and steroidogenesis. In this chapter, we review contemporary
information on purinergic action in ovarian cell physiology and state its relevance in
this field.
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1. Introduction
The ovary is a complex cell system where folliculogenesis and steroid hormone
synthesis take place. These processes involve dynamic changes in the cellular
populations of this tissue and highly precise mechanisms of regulation.
Folliculogenesis requires a complex coordination of three stages: recruitment, which
is the initial growth of a group of follicles from the reserve pool; selection, during
which a subgroup from this pool of recruited follicles survives and grows, while the
remainders suffer atresia; and dominance, in which the follicles that will be ovulated
reach the preovulatory stage and increase their size, while the subordinate follicles
arrest their growth. It is well known that the initial stages of folliculogenesis are
independent of gonadotropins, whereas the advanced stages depend on these hor-
mones. At the same time, selection and dominance stages implicate the elimination of
subordinated follicles by apoptosis; thus, a coordinated set of events directs growth
and surveillance of some follicles and disappearance of others with extreme preci-
sion [1].
Folliculogenesis involves constant rearrangement in ovarian cellular architec-
ture. A primordial follicle is formed by an oocyte surrounded by a layer of
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squamous epithelial cells and is arrested in the diplotene phase of meiosis I. When it
is recruited and enters the growing stage, granulosa cells change their shape from
flat to cuboid, starting their proliferation; this entity is known as primary follicle.
The granulosa layer continues proliferating to adopt a stratified epithelium; then,
the theca layer surrounding the follicle emerges. This layer is innervated and
vascularized conforming a secondary follicle. Inside the follicle, three to four cavities
filled with fluid are formed; the cavities fuse and form the antrum. This stage is
known as antral follicle. Antrum formation implicates the emergence of two
granulosa populations: cumulus cells in contact with the oocyte and mural cells
attached to the follicular theca. These follicles grow until reaching the preovulatory
stage [1]. Changes in follicle development are orchestrated by diverse cellular mes-
sengers (reviewed in [2]).
Moreover, synthesis and secretion of ovarian steroid hormones are coordinated
by the somatic components of the follicle; thus, cholesterol and acetate uptake from
the blood by the theca layer allows the synthesis of androgens that are aromatized
into estrogens in the granulosa cells [3]. This process is finely regulated by the
coordinated action of intraovarian and endocrine components.
All these dynamic processes are organized at distinct levels by endocrine, ner-
vous, and autocrine-paracrine mechanisms acting with high systematic precision.
Recent findings suggest that purinergic signaling participates in the control of
cellular process in the follicle cells, making it a new player in the network of signals
regulating the cellular biology of ovarian physiology. Given that follicle cell types
have defined roles and are typical for each follicular growth stage, receptor expres-
sion in each of these cell types suggests a potential physiological role; thus, we
organized the information of this chapter to cover the role played by purinergic
receptors in ovarian physiology.
2. Purinergic system
From a chemical perspective, purines are defined as nitrogen-containing het-
erocyclic aromatic compounds formed by the fusion of a pyrimidine and an imid-
azole ring (in total, five carbon and four nitrogen atoms). The purine molecule can
be associated with an amino group, such as adenine (6-amino purine), or with
amino and keto groups, such as guanine (2-amino-6-oxy purine). The existence of
functional groups that are weakly acidic next to a system of conjugated dienes
favors the relocation of a proton along the molecule, allowing the formation of
constitutional isomers called tautomers. The principal tautomeric equilibriums in
purine molecules are amino (predominant)-imino forms and lactam (predomi-
nant)-lactim forms [4].
Purines are part of important informational polymers, such as nucleic acids
(DNA and RNA), and of various biomolecules with metabolic and functional
significance such as bioenergetic factors (ATP and GTP), redox coenzymes (NAD
(P)H/NAD(P)+, FMNH2/FMN
+, and FADH2/FAD
+), biochemical crossroad metab-
olites (coenzyme A), and signaling molecules (cyclic AMP, cyclic ADP-ribose,
nicotinic acid adenine dinucleotide phosphate [NAADP]) and ligands for purinergic
receptors. Caffeine and theobromine are naturally occurring purines in plants [5].
In this section, we will refer exclusively to ATP, adenosine (ADO), and other
related molecules as factors in cellular communication and coordinators of
metabolic networks (Figure 1).
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Figure 1.
Purines in cellular signaling and metabolic networks. The figure depicts two cells in communication using
purines as signaling molecules. Released ATP is recognized by two types of receptors (P2X, ionotropic, and P2Y,
metabotropic). ATP can be hydrolyzed by different ectonucleotidases (such as CD39 and CD73) to be
transformed in less phosphorylated nucleotides (ADP and AMP) and eventually to the nucleoside adenosine
(ADO). The receptors that mediate ADO’s actions are all metabotropic. Thus, purinergic signaling is the result
of the types of receptors present in the cellular system, as well as the variable proportion of adenine nucleotides
and ADO that result from the enzymatic activities of the expressed ectonucleotidases. There are membrane
transporters with the capacity to transfer ADO to the cellular inside. Within the cell, ADO can be transformed
in multiple metabolites and act as modulator of strategic metabolic pathways. ADO is catabolized by adenosine
deaminase (ADA) resulting in a set of purines that culminates with uric acid (a mild antioxidant) with
xanthine as an intermediary with the capability to generate the anion superoxide (O2
). By the action of
adenosine kinase, ADO can turn into a nucleotide (AMP) that is a modulator of the AMPK, which is an
important enzyme to regulate energy homeostasis. AMP can be further phosphorylated to ADP and ATP.
Eventually, ATP can go to the extracellular space to fulfill its messenger role by exocytosis or by specialized
channels (pannexin and connexin hemichannels). The proportion of adenine nucleotides (energy charge) is an
important modulator of the equilibrium between catabolic and anabolic reactions. It has been reported that
ADO is able to increase the cellular energy charge in the liver. When ADO binds homocysteine to form
S-adenosylhomocysteine (SAH), it can also influence the transmethylation and transsulfuration pathways.
SAH is usually formed when the methylating agent S-adenosylmethionine (SAM) transfers a methyl moiety to a
given substrate. Interestingly, SAM can also participate in the synthesis of polyamines by transferring an
aminopropyl group from decarboxylated SAM to putrescine. Homocysteine is joined to serine to form the
intermediary cystathionine, which is transformed into cysteine and the intracellular messenger H2S.
Meanwhile, cysteine can be incorporated into the redox and antioxidant molecule glutathione (GSH) or can be
converted into the osmolyte taurine. Hence, a condition in which ADO is increased beyond a threshold may
accumulate SAH with the consequent interruption of the methylating reaction and the promotion of polyamine
synthesis, as well as the reduction of homocysteine availability and the decrease in cystathionine and all its
derivatives.
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Adenine-related molecules are ubiquitously present in all living beings. ATP
(a nucleotide) and ADO (a nucleoside) are easily interconverted by a set of three
phosphorylation/dephosphorylation steps. Interestingly, this purine conversion
involves different mechanisms when it takes places either inside or outside the
cellular milieu. Intermediates of these reactions are AMP and ADP nucleotides,
whereas some metabolically important ADO derivatives are uric acid, S-adenosyl
methionine (SAM), and S-adenosylhomocysteine (SAH). Various physiopathologi-
cal events modulated by ATP and/or ADO have been reported, including sleep,
immunity, tumorigenesis, platelet aggregation, vasodilation, inflammatory and
hypoxic responses, and antioxidant status [6]. Overall, adenine nucleotides and
ADO are interconnected signaling factors that activate specific membrane receptors
and act as metabolic regulators that coordinate the equilibrium between anabolic
and catabolic reactions [7].
2.1 Purinergic communication
ATP and ADO are well-known signaling molecules. Both purines have the
capacity to promote a set of cellular responses by acting through specific membrane
receptors, either by activating ionic conductance or by promoting the formation of
second messengers. Two families of receptors for purine ligands have been charac-
terized: (1) P1 or ADORA receptors, which are G-coupled metabotropic adenosine
receptors and are classified as A1 and A3 (associated with adenylate cyclase inhibi-
tion and formation of IP3 and diacylglycerol) and as A2A and A2B (both activate
adenylate cyclase), (2) P2 receptors, which recognize ATP as a principal ligand but
also a variety of related compounds. P2 receptors are divided into ionotropic recep-
tors (P2X1–7) and G-coupled metabotropic receptors (P2Y1, P2Y2, P2Y4, P2Y6,
P2Y11–P2Y14). In addition to ATP, P2Y receptors can be recognized by alternative
ligands such as ADP, UTP, UDP, and UDP glucose [8].
Unlike other signal transduction systems, purinergic signaling involves the
actions of two interconvertible ligands, ATP and ADO, within the same system.
Interestingly, these ligands exert complementary or antagonistic actions on each
other [9]. For example, epithelial-mesenchymal transition (EMT), a cellular plas-
ticity process important in phenotypic programming of metastatic tumors, can be
upregulated by ATP in SKOV-3 cells (from ovarian carcinoma) but downregulated
by ADO [10]. This circumstance indicates that enzymes (ectonucleotidases)
allowing the sequential conversion from ATP to ADO are a potential regulatory
node that controls diverse cellular and physiological responses.
Four families of extracellular enzymes that transform purine nucleotides into
ADO and phosphate are known: (1) ENTPD/CD39 (ectonucleoside triphosphate
diphosphohydrolase) forms AMP from ATP/ADP; (2) ENPP (ectonucleotide
pyrophosphatase) forms AMP from ATP/ADP/ADP-ribose; (3) alkaline phospha-
tase hydrolyzes different nucleotides to be transformed into ADO; and (4) NT5E
(ecto-5′-nucleotidase) forms ADO from AMP [11]. It is expected that the combined
and sequential activities of these enzymes in a given cell system result in a highly
variable and potentially fine-tuned proportion of adenine nucleotides (ATP, ADP,
and AMP) and ADO. Therefore, the physiological equilibrium between ATPergic
and adenosinergic transmissions should be considered as a unique and emergent
property of each cell system.
2.2 Purine-related metabolites
Adenine purines are key elements in metabolic network control. The proportion
of adenine nucleotides dictates the direction of anabolic and catabolic processes by
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means of the regulatory parameter known as energy charge (ATP + ½ADP/
ATP + ADP + AMP). In this context, ATP and AMP act as allosteric factors for a
variety of enzymes that are important in the bioenergetic status of the cell: phos-
phofructokinase 1 (glycolysis), aspartate carbamoyltransferase (pyrimidine synthe-
sis), and glycogen phosphorylase (glycogenolysis). Interestingly, ADO treatment is
one of the few cases that can upregulate the energy charge in vivo [12]. Another
example of how the AMP/ATP ratio influences the metabolic networks is AMP
kinase (AMPK) activation. AMPK is a strategic kinase that modulates the fasting
response by phosphorylating and activating key catabolic enzymes [13].
ADO is a crossroadmetabolite; it can be turned into nucleotides (first in AMP by
adenosine kinase), or it can originate active catabolites such as xanthine (a source of
superoxide) and uric acid (a terminal metabolite andmild antioxidant). The produc-
tion of ADO in the liver and its transport through the blood are controlled by the
circadian timing system; eventually, these mechanisms allow the 24-h rhythmic pres-
ence of purine rings in the nervous system,which arenecessary for the onset of sleeping
[14]. ADO has also been used as a hepatoprotective and antitumoral agent [15].
ADO also plays a role in the transmethylation and transsulfuration pathways, with
SAM as a central metabolite for both. Initially, ATP activates methionine, which in
turn generates SAM, the main cellular methylating agent. Some principal methylated
molecules are phospholipids (phosphatidylethanolamine turns into phosphatidylcho-
line), catecholamines (adrenaline turns into noradrenaline and serotonin into mela-
tonin), and nucleic acids (during epigenesis and RNA processing). SAM is
transformed into SAH, which is hydrolyzed into ADO and homocysteine. In this
metabolic step, ADO levels can modulate the methylation process, as high ADO
favors SAH synthesis, thus blocking methyl donation. SAM is also a substrate for
polyamine synthesis. In the presence of serine, homocysteine is converted into
cystathionine. Within the mitochondria, this intermediate is the precursor of both the
gasotransmitter H2S and the principal antioxidant agent, glutathione [16].
2.3 Membrane transporters
Extracellular and intracellular purine dynamics are interconnected, mainly
through specialized protein transporters that allow ATP and ADO to transit
throughout the plasma membrane.
ATP exists at millimolar levels within the cell. It exits to the extracellular space,
where it acts as a cellular messenger through two main paths: (1) exocytic, which
involves secretion of vesicles mainly derived from Golgi and secretory ATP-
containing granules by means of Ca2+-dependent membrane depolarization and (2)
conductive, in which the ATP efflux is carried out by different ion channels:
hexamers of connexin subunits, assemblies of pannexin subunits, volume-regulated
anion channels, and maxi-anion channels [17]. As mentioned, ATP can lose its phos-
phates in the extracellular space and transform into ADO. In turn, ADO can return to
the intracellular milieu by the action of two types of carriers; one is driven by a
facilitated diffusion event (sensitive to dipyridamole), and the other mobilizes ADO
by an active process regulated by the Na+-transmembrane gradient [18]. Overall, a
net flux of purines can be visualized: first, purine rings exiting as ATP and eventually
purines returning to the cell interior as ADO. Indeed, this cycle involves the net efflux
of phosphate as well as the net conversion of intracellular ATP into ADO.
2.4 Integrative considerations
The transformation among purine molecules inside and outside the cell has the
potential of intricately regulating both purinergic signaling and metabolic control.
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To propose a model of this interaction, the following considerations are necessary:
(1) at least three compartments should be taken in account—extracellular, cyto-
plasmic, and mitochondrial. However, if there is segregation of receptor
populations in different membrane domains (e.g., signalosomes), the extracellular
compartment could be more complex. (2) It is important to know the principal
metabolite and intermediate levels in the process; indeed, the concentrations of
these factors are expected to fluctuate, but knowing average levels is necessary. For
example, ATP is at [mM] in the intracellular milieu, but when it is released in the
pericellular space, it changes from [nM] to [mM] [19]. (3) It is important to know
which receptors are present in a given cell system, as well as their physical constants
(Kd and Bmax). (4) It is convenient to have a clear idea of the activities and
regulation of all ectonucleotidases and their corresponding carriers. (5) In the same
context, determining the presence of purine metabolizing enzymes and kinetic
constants (Km and Vmax) is required. (6) It is necessary to know the conforma-
tional status of all proteins involved in the purine cycle in order to detect potential
allosteric modulation.
3. Purinergic signaling in the ovary
3.1 Granulosa and luteal cells
Early studies analyzed the effects of ADO over the gonadotropin-induced cAMP
production in granulosa and luteal cells. In rat and human granulosa cells, ADO
incremented the accumulation of cAMP in response to follicle-stimulating hormone
(FSH); similar effects were observed when human luteal cells were stimulated with
human chorionic gonadotropin (hCG) or luteinizing hormone (LH), revealing the
possibility that ADO is a gonadotropic modulator [20–23]. According to the dual
role of ADO in metabolism and cell signaling, it was originally proposed that ADO
effects were mediated by two mechanisms acting synergically: ADO translocation to
the cytoplasm where the nucleoside can sustain the increment of cytosolic ATP and
extracellular activation of specific membrane receptors [20].
In primary cultures of rat granulosa cells, incubation with ADO incremented
intracellular ATP; dipyridamole blocked this effect, indicating ADO uptake through
specific transporters [22]. The regulation of adenylate cyclase (AC) activity by ADO
analogues was investigated in membranes isolated from the whole ovaries in follic-
ular growth. It was observed that adenosinergic agonists incremented adenylate
cyclase (AC) activity. Pharmacological approaches suggested that the effect of ADO
analogues was mediated by the A2A receptor because it was strongly promoted by
5’-N-ethylcarboxamidoadenosine (NECA) and antagonized by 8-phenyltheo-
phylline (8-PTH) [24]. Similar findings were observed in membranes from
luteinized ovaries from superovulated rats induced by injection with pregnant mare
serum gonadotropin (PMSG) and in homogenates of isolated cells from luteal bod-
ies; moreover, it was shown that ADO analogues incremented progesterone syn-
thesis. In these preparations, pharmacological evidence also indicated the
participation of A2A receptor in the adenosinergic induction of cAMP accumula-
tion, suggesting that ADO is a paracrine regulator of the luteal body’s endocrine
activity [25].
In addition, it has been shown that in ovine luteal cells, ADO increases the effect
on luteotropins [hCG] as well as prostaglandins (E1 and E2) over progesterone
production and inhibits the antigonadotropic and luteolytic effect of prostaglandin
F2α (PGF2α) [20, 26]. Purinergic responses in ovarian cells were described before
cloning P2 receptors. The effect of adenine nucleotides on cytosolic concentration
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of Ca2+ ([Ca2+]i) was first investigated in human luteal cells and in porcine
granulosa cells; it was observed that nucleotides elicited an increment of [Ca2+]i in
both cell types. Moreover, in luteal cells, these compounds also induced an increase
in progesterone and estradiol secretion [27]. Consistently, in granulosa from hen
preovulatory follicles, ATP, and other adenine nucleotides also induced an incre-
ment of [Ca2+]i; the pharmacological characterization of this response revealed that
it was mediated by intracellular Ca2+ release and dihydropyridine-insensitive Ca2+
channels according to P2Y receptor activation [28]. In human granulosa cells, it was
determined that ATP responses were dependent on Ca2+ released from intracellular
stores [29].
The molecular description of the P2Y2 receptor (then named P2U because of its
sensitivity to UTP) in human granulosa-luteal cells (GLC) was made by Leung’s
group in British Columbia [30]. They detected the transcript of P2U receptor by
Northern blot and reported the elevation of cAMP promoted by hCG. The stimula-
tion of these cells with UTP/ATP induced an increment of [Ca2+]i associated with
phospholipase C (PLC) activation. Downstream of this pathway, protein kinase C
(PKC) was activated, and it negatively modulated the P2Y2-dependent [Ca2+]i
response [31]. The molecular machinery and mechanism involved in the purine-
induced increment of [Ca2+]i have been studied. ATP-induced Ca
2+ release medi-
ated by activation of PLC and inositol triphosphate (IP3) production. Indeed, IP3
and ryanodine receptor (RyR) expression in GLC has been demonstrated. The
increment of ATP-induced [Ca2+]i was modulated by substances interfering with
the activity of both RyR and IP3R, revealing an interplay between both receptors to
amplify the purinergic [Ca2+]i signal [32]. Moreover, it was described that GLC
expresses three isoforms of IP3R, RyR, and thapsigargin-sensitive Ca
2+-ATPase
(SERCA) [33].
Electrophysiological and Ca2+ imaging studies in the GFSHR-17 cell line from
granulosa determined that P2Y2 and P2Y4 receptor stimulation induces Ca2+ mobi-
lization and hyperpolarization. Both responses were sensitive to the PLC inhibitor
U73122 and to the IP3R antagonist 2-aminoethyl diphenyl; hyperpolarization was
mediated by Cl channels, probably dependent on intracellular Ca2+ [34].
Moreover, it was shown that the P2Y2 (P2U) activation in human GLC induced a
decrease in the LH-dependent cAMP levels; this antigonadotropic effect was medi-
ated by PKCα activity [35]. In parallel, it was shown that P2Y2 stimulation also
activated extracellular mitogen-regulated kinases (ERK) through a Gαq-dependent
pathway; ERK activity was responsible for inhibiting LH-dependent production of
progesterone induced by P2Y2 activation [36]. Further experiments revealed that
phospho-ERK translocates to the nucleus and regulates cell proliferation by early
growth-1 (egr-1) and c-raf-1 responses [37]. These data clearly show that the
purinergic response mediated by P2Y2 in GLC can be an important modulator of
gonadotropic actions and granulosa cell physiology.
Expression of the P2Y6 receptor was observed in murine GLC. Its stimulation
with the selective agonist UDP incremented cell viability and progesterone but did
not affect estradiol production. This effect on steroidogenesis was concomitant with
a negative regulation of enzymes corresponding to Δ4 steroidogenic pathway,
CYP11A, 3β-HSD, and StAR. The effects were blocked by the antagonist MRS2578
before UTP stimulus [38]. These results suggested that purines acting through P2Y6
regulate luteal body viability and steroidogenic function.
In human GLC, extracellular ATP promoted apoptosis by activating P2 recep-
tors. These receptors elevated [Ca2+]i, which in turn activated Ca
2+-dependent K+
channels, leading to membrane depolarization [39]; however, the specific receptor
involved in this response was not identified. These observations were confirmed by
a later study that demonstrated the participation of apoptotic marker caspase-3
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[40]. This effect was apparently not consistent with previous observations regard-
ing ATP actions in GLC, but it could be explained by the differential sensitivity of
distinct P2 receptors [41]. It is possible that extracellular concentration of ATP
and the expression of P2 receptor determine the specific effect of purinergic
stimulation.
Recently it was described that the P2X7 receptor is expressed in mouse luteal
cells. Its activation with ATP or BzATP induced an antiproliferative effect by
regulating the expression of cyclin D2 and cyclin E2, as well as the phosphorylation
of mitogen-activated protein kinase p38 [42]. The result suggests a role for the P2X7
receptor in luteal body function.
The purinergic system is well represented in GLC. A set of purinergic receptors
can modulate basic cellular processes such as proliferation, apoptosis, and steroido-
genesis. Growing evidence indicates that purines are important regulators of GLC,
but further studies are necessary to reinforce their role in ovarian physiology.
3.2 Theca cells
The theca cell layer is an enclosure of cells that surrounds the oocyte during
folliculogenesis. It is crucial for maintaining the structural integrity of the follicle as
well as for regulating nutrient influx to the avascular GCL [43, 44]. Theca is also the
site for the synthesis of steroid hormones, specifically androgens (testosterone and
dihydrotestosterone), from acetate or cholesterol into estrogens by granulosa cells
in an LH-dependent manner [3]. In addition, theca is the only component of the
follicle that is innervated by sympathetic and parasympathetic nervous systems,
implicating that this layer functions as a complex integrator of endocrine and neural
information [45].
When a primary follicle has one or two layers of granulosa cells, an outer
granulosa cell layer differentiates into theca cells and, together with recruited theca
precursor cells from the stroma, forms the theca cell layer surrounding the oocyte
[44, 46]. Some pathophysiological reproduction-related conditions such as infertil-
ity or polycystic ovarian syndrome are often the result of dysfunctional activity of
theca cells during ovulation and follicle development [47, 48].
The theca cell layer contacts the rich microvasculature system surrounding each
follicle and integrates signals from autonomic innervation [49]. It has been demon-
strated that ATP can be co-released with noradrenaline from terminals of the
peripheral nervous system [50] and as a result of mechanical stress and changes in
cell volume in the oocyte [51]; thus, ATP is a relevant modulator of cellular com-
munication between the theca cell layer and surrounding oocyte cells.
Purinergic signaling has been described in female reproductive organs, and
evidence has shown that ATP in the extracellular space participates in the physio-
logical regulation of the ovary [52]. The first characterization of purinergic signaling
in theca cells showed the functional expression, and activation of P2X7 receptors
induced cell death, an important mechanism for the onset and physiological pro-
gression of follicle atresia [53]. P2X7 receptors have also been associated with the
inhibition of luteal cell survival and proliferation, pointedly in small luteal cells,
which have been suggested as theca-derived luteal cells [42].
On the other hand, there is also evidence of the expression of uridine triphos-
phate (UTP)-sensitive P2Y receptors in theca cells P2Y2 and P2Y6, but not P2Y4
[54]. In this system, stimulation of the expressed P2Y receptors with UTP in cul-
tured theca cells induces the activation of mitogenic-signaling pathways that pro-
mote cell proliferation [54]. This finding is a relevant pathophysiological indication,
since a slow but maintained proliferation takes place in polycystic ovarian syn-
drome [47].
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Furthermore, an interaction between adenosine receptor A2 and P2Y receptors
has been described in theca of Xenopus ovarian follicles. The authors suggested that
this association took place when both the epithelial and theca cell layers of the
oocyte were intact [55].
Collectively, these findings suggest that a tight regulation of purinergic expres-
sion and signaling must be in place for the theca cell layer to function properly and
communicate with neighboring cells.
3.3 Cumulus complex
The organized structure of the cumulus-enclosed oocyte (CEO) complex corre-
sponds to a specialized GLC surrounding the oocyte. Cumulus cells secrete factors
to regulate oocyte maturation and maintain meiotic arrest [56]. It was reported that
porcine and murine follicular fluid contains purine compounds that presumably
participate in CEO functions, suggesting that it could be an important signal to
trigger physiological events [57, 56]. Until recently, purinergic receptors were
identified and characterized in CEO, indicating that purinergic signaling partici-
pates in CEO physiology [58, 59].
When Eppig et al. discovered that the main components of follicular fluid were
nucleotide-derived metabolites [60] and established a relationship with follicle
maturation [56, 57], they hypothesized that the local purinergic metabolism in the
ovarian fluid can be involved in oocyte maturation or may participate in other
aspects of follicular functions.
In these studies, the concentration of nucleotide compounds in murine follicular
fluid was determined using high-performance liquid chromatography (HPLC).
They identified two purine compounds: hypoxanthine and ADO, with concentra-
tions in ranges of 2–4 and 0.3–0.7 mM, respectively. They also showed that these
purines affected the CEO by maintaining the meiotic arrest [56].
Eppig et al. also analyzed the same compounds in porcine follicular fluid; they
identified that hypoxanthine at 1.4 mM is the major inhibitory component produc-
ing a transient inhibition [61]. This observation contrasted with that of other labo-
ratories which had failed to detect inhibitory activity in follicular fluid.
On the other hand, the cellular effects of purinergic ligands were studied by Ca2+
imaging and electrophysiological approaches. In 2002, two reports elucidated which
purinergic receptor was expressed in CEO cells. The first report of P2Y expression
in CEO began with an interesting observation that ATP could stimulate an intracel-
lular Ca+2 transient. Experiments using the CEO complex and applying ATP or UTP
to the extracellular solution induced a wave of Ca+2mobilization from cumulus cells
to the oocyte through gap junctions, suggesting that ATP was involved in oocyte
maturation; moreover, they showed that the response involved the P2Y2 receptor.
Since gonadotropin hormones, follicle-stimulating hormone (FSH), and luteinizing
hormone (LH) had no effect on Ca+2 changes [59], the authors concluded that ATP
was the specific messenger to mediate calcium signals involved in oocyte matura-
tion in the CEO complex.
In another report, the responses generated by a putative purinergic receptor
expressed in the CEO were identified and characterized. Employing the voltage
clamp technique with two electrodes, the authors observed depolarization
responses when extracellular ATP was applied. RT-PCR analysis revealed a product
correspondent to the P2Y2 receptor, suggesting that calcium mobilization is depen-
dent on this receptor. A detailed description of distinct currents generated from
several ionic channels, such as Ca+2-dependent Cl current, voltage-dependent K+
currents, and a cationic current mainly driven by Na+, was provided. The authors
concluded that both purinergic receptors and ionic channels were located in CEO
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cells that transmitted their electrical signals to the oocyte via gap junctions [58].
These data support the idea that P2Y2 is an important element in paracrine signaling
in regulating CEO complex physiology. Future studies are required to determine the
mechanisms involved in CEO functions and oocyte maturation by ATP stimulation.
3.4 Ovarian surface epithelium
Ovarian surface epithelium (OSE) is a monolayer surrounding the ovary. It is
composed of a single flat layer of squamous-to-cuboidal epithelial cells featuring
distinguished epithelial and mesenchymal markers. OSE is essential during ovula-
tion to promote follicular rupture and release the oocyte [62] and for postovulatory
repair of the ovary [63].
Initial and important studies were led by Nelly Auersperg to characterize and
identify epithelial and mesenchymal markers, hormonal and growth factor recep-
tors, and physiopathological role, with the idea that OSE is determinant in the onset
of ovarian carcinoma [64]. During ovulation, the OSE is involved in three main
phases: apex formation, rupture, and repair [65].
The initial phase starts with the actions of luteinizing hormone (LH) and triggers
apex formation at the rupture site of the ovarian surface [66]. In the second phase,
OSE cells initiate a lytic cascade [62, 67, 68], releasing proteolytic enzymes to
degrade the basal lamina, the tunica albuginea, and ovarian cells of the mature
follicle. The digested matrix, follicular wall disintegration, and peeling of OSE cells
create a wound stigma that facilitates oocyte release. Finally, the repair phase
consists in wound closure by postovulatory cell proliferation and migration [69].
Nevertheless, the signaling involved in these phases during ovulation in the OSE
is unclear. Purinergic signaling was suggested as a part of intraovarian modulation
due to a certain purinergic receptor expressed in the OSE committed in physiolog-
ical processes. Recently, Vazquez-Cuevas et al. demonstrated the expression of
ligand-activated ion channel P2X7 in OSE. In primary cultures of mouse OSE, they
observed that BzATP induced a non-desensitizing increment of [Ca+2]I, and this
response was blocked with A438079, a selective antagonist of the P2X7 receptor.
The functional role of P2X7 was investigated in situ by TUNEL assay. P2X7 stimu-
lation with BzATP induced apoptosis in OSE cells and was differential throughout
the oestrous cycle; DNA fragmentation was greater during proestrous [70]. These
findings contribute to the idea that local factors, such as ATP, may participate in a
proposed cyclic proliferation-death equilibrium of the OSE cell layer in the ovula-
tory process.
Understanding purinergic signaling and receptor expression in the OSE will help
to decipher the mechanisms underlying ovary physiology and pathology. However,
more studies need to contribute evidence related to homeostasis and postovulatory
repair. Some studies regarding OSE-derived cancer cells will be discussed in the
next section.
4. Purinergic signaling in ovarian cancer
Although the specific roles for purinergic signaling in ovarian physiology are not
completely understood, significant advances have been made in deciphering the
role of purines in cancer. Plenty of information supports that purinergic system
elements have a role in cancer progression, and this implicates that they are poten-
tial therapeutic targets. Here we will address the relevance of the purinergic system
in ovarian cancer (OC).
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Ovarian cancer (OC) is considered the most lethal gynecological malignancy, as
it is usually diagnosed by the time the tumor has spread to other regions [71]. OC is
the seventh most common type of cancer in women, and patients have a low
survival rate [72]. Early detection of the disease proves difficult due to unspecific
symptoms such as abdominal pain and bloating, whereas advanced stages are con-
fused with gastrointestinal illnesses [73]. Although OC can arise from any of the
cells located in the ovary (germ, stroma, and the epithelium), it is acknowledged
that almost 90% of OC is derived from the OSE. According to histological charac-
teristics, epithelial ovarian cancer (EOC) is classified in serous, endometrioid, and
clear cells and in mucinous carcinomas [74].
Ovarian tumors frequently show disseminated metastasis through ascites in the
peritoneal cavity. OC cells are exfoliated from the primary tumor surface to the
peritoneal fluid, where they survive as single cells or multicellular aggregates. These
cells acquire resistance to anoikis, have stem cell properties, and are plastic in terms
of switching between epithelial and mesenchymal phenotypes. In addition to cancer
cells, the malignant ascite microenvironment has normal cell types, such as plate-
lets, associated fibroblast, and immune cells, which support and assist cancer cells
[75, 76]. This distinctive tumor microenvironment (TME) has paracrine and auto-
crine signals that support cancer cell proliferation, death evasion, dissemination,
and invasion to peritoneal organs. Therefore, understanding cellular and molecular
mechanisms that promote progression of the disease is very relevant.
Purinergic signaling has emerged as an important regulator of tumor growth
[77]. The following facts support this assertion: (1) cancer cells increase in meta-
bolic rate [78]; (2) ATP and ADO levels increase in the tumor interstitium [79, 80];
(3) purinergic receptors are expressed in tumor cells [77]; and (4) high CD73
ectonucleotidase expression is a prognosis factor for several types of cancer [81].
Early studies of purinergic signaling in ovarian carcinoma-derived cells (OCDC)
evaluated the effects of ATP on [Ca2+]i mobilization. It was demonstrated in
OVCAR-3 and SKOV-3 cell lines that stimulation with ATP in a μM range induced a
biphasic response that consisted in a rapid peak followed by a smaller and sustained
plateau phase. In addition, chelation of Ca2+ abrogated the slower response induced
by ATP, while the rapid response was maintained. Furthermore, low concentrations
of ATP induced SKOV-3 and OVCAR-3 cell proliferation [82, 83]. These pioneer
works indicated that OCA cells were responsive to ATP. Furthermore, the biphasic
response induced by ATP suggested that these cells could express two types of
purinergic receptors: channels operated by ligands and G protein-coupled receptors
(GPCRs).
In other OCDC lines (EFO-21 and EFO-27), the presence of P2Y2 receptor was
described, and ATP response was monitored through intracellular Ca2+mobilization
and phospholipase D (PLD) activation. In addition, ATP downregulated basal cell
proliferation and the proliferation induced by fetal calf serum (FCS) [84]. How-
ever, in IOSE-29 (preneoplastic) and IOSE-29EC (neoplastic) cell lines, which also
express P2Y2, ATP-stimulated cell growth through the MAPK/ERK kinase activa-
tion [85]. These findings showed that ATP effects differ across cell lines, which
could be associated with the activated intracellular mechanism.
Regarding the expression of P2X receptors in OCDC lines, some of the first
reports evaluated P2X7 expression in OC biopsies as in SKOV-3 and OVCAR-3 cells.
P2X7 expression in human ovaries is confined to the OSE, whereas in EOC biopsies,
its expression is wider and localized in transformed zones [86, 87]. Additionally,
receptor functionality was evaluated in cell lines, and it was demonstrated that its
stimulation induces ERK and AKT phosphorylation, whereas its inhibition reduces
cell viability [87]. The latter result was surprising due to previous findings that
associated P2X7 receptor activation with apoptosis.
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An important feature of cancer cells is their ability to migrate and invade sec-
ondary organs. One process that allows OC cells to dissociate from primary tumors
and survive in peritoneal fluid is the EMT, in which cells switch from an epithelial
to a mesenchymal phenotype. Even though this process was first described in
embryonic development, today its role in cancer is well accepted. The involvement
of purines in EMT has recently been reviewed [9]. It has been proven that P2Y2
stimulation promotes SKOV-3 cell migration, and this effect is associated with
epithelial growth factor receptor (EGFR) transactivation. Moreover, expression of
EMT inductors such as SNAIL and TWIST was promoted in response to UTP; in
addition, the intermediate filament vimentin was augmented by this pharmacolog-
ical stimulus. Interestingly, addition of apyrase (Apy) to cell medium, with the aim
of removing extracellular ATP, decreased cell migration and favored an epithelial-
like phenotype due to the relocation of E-cadherin to SKOV-3 cellular junctions
[88]. The authors concluded that products obtained by ATP hydrolysis (i.e., ADO)
promoted an epithelial phenotype, while P2Y2 activation by ATP analogues pro-
moted a mesenchymal one.
As previously mentioned, ATP and ADO concentrations increase in cancer.
Although ATP is within a low nM range in the healthy interstitium, it increases to
μM concentrations (800 μM) near the tumor. This new evidence is relevant
because extracellular ATP was monitored in vivo in tumors induced with OVCAR-3
cells in nude mice [80]. Given that extracellular ATP can be hydrolyzed by mem-
brane ectonucleotidases (CD39 breaks ATP into ADP and AMP, and CD73 hydro-
lyzes AMP to ADO), it could be assumed that the increase in extracellular ATP is
directly correlated with the increase in ADO. Even though extracellular ADO has
not been measured in tumors in vivo, there is evidence that ADO levels increase in
tumor microdialysates and are more abundant at the core of the tumor [79]. In vitro
studies have also indicated that OCDC-derived cell lines release ATP to the cell
medium [10, 89].
Correspondingly, ADO function has been evaluated in several types of cancer,
and an immunosuppressive role has been proposed for this molecule through
ADORA2A receptor activation. Specifically, in OCDC cell lines, it has been demon-
strated that ADO inhibits antitumor activity of T and natural killer (NK) cells.
Moreover, OC biopsies, OC-derived primary cultures, and cell lines express func-
tional CD39 and CD73 [89]. Therefore, strategies such as CD39 and CD73 inhibition
with the aim of reducing extracellular ADO concentrations have been performed,
and an improved immune response was described using antibodies against these
enzymes [89]. CD73 expression has also been associated with poor prognosis in
high-grade serous ovarian carcinoma (HGSOC) [90]. Recent evidence demon-
strated that CD73 expression in primary-derived OC promotes stemness and tumor
growth and proved that this enzyme acts as an EMT promoter [91], allowing us to
recognize CD73 as a promising target for OC.
Eventually, ADO in the extracellular milieu activates ADORA receptors (also
known as P1), whose expression has also been characterized in different OCDC
lines (e.g., in SKOV-3, CAOV-4, and OVCAR-3). Transcript and protein presence
of the four ADORA receptors has been described in the previously mentioned cell
lines, with ADORA2B and ADORA3 expression being more abundant; their func-
tionality was demonstrated through cAMP measurement in response to specific
agonists [92, 93].
SKOV-3 cell incubation with Apy, ADO, or NECA, an ADORA2 receptor ago-
nist, decreases cell migration. A transcriptional study using a microarray demon-
strated that treatment with ADO reduced expression of WNT2, WNT6, WNT10B,
and FGF-18, all of which activate signaling pathways involved in EMT in OC [10].
On the other hand, expression of ARPC4 and RAPGEG1 transcripts associated with
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cytoskeleton rearrangement increased [10]. Regarding ADORA2 expression, it has
been proven that the addition of NECA reduces cell viability and promotes apopto-
sis in CAOV-4 and OVCAR-3 cell lines [92]. Activation of ADORA3 in OCA-derived
cell lines is associated with apoptosis induction and G1 phase cell cycle arrest [94].
Altogether, the evidence highlights purinergic signaling as an important regulator in
EOC progression.
5. Conclusion
Since Geoffrey Burnstock proposed his purinergic hypothesis in the early 1970s,
enormous advances have been achieved in describing the molecular elements that
conform the purinergic system and in our understanding of a complex system that
is constituted as a continuous metabolic network together with the dynamic events
in extracellular signaling. Indeed, the specific actions of purinergic signaling in each
system are still being discovered, and its study is a growing field of knowledge. In
this chapter, we summarize current knowledge of purinergic signaling in the ovary,
where an extensive and specialized expression of purinergic receptors and purine-
handling enzymes are observed. The accumulated evidence depicts an emergent
and complex system, and at the same time, it raises important questions with deep
physiological and pathological implications.
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AC adenylate cyclase
ADO adenosine
ADP adenosine diphosphate
AMP adenosine monophosphate
AMPK AMP kinase
Apy apyrase
ATP adenosine triphosphate
[Ca2+]i intracellular concentration of Ca
2+
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EGFR epithelial growth factor receptor
egr-1 early growth-1
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FADH2/FAD
+ reduced/oxidized flavin adenine dinucleotide
FMNH2/FMN
+ reduced/oxidized riboflavin-5′-phosphate
FSH follicle-stimulating hormone
GLC granulosa-luteal cells
GPCRs G protein-coupled receptors
GTP guanosine triphosphate
hCG human chorionic gonadotropin
HGSOC high-grade serous ovarian carcinoma
HPLC high-performance liquid chromatography
LH luteinizing hormone
NAADP nicotinic acid adenine dinucleotide phosphate
NAD(P)H/NAD(P)+ reduced/oxidized nicotinamide adenine dinucleotide
phosphate
NECA 5’-N-ethylcarboxamidoadenosine
NK natural killer
NT5E ecto-5′-nucleotidase
OC ovarian cancer
OCDC ovarian carcinoma-derived cells
OSE ovarian surface epithelium
PGF2α prostaglandin F2α
PLD phospholipase D
PLC phospholipase C
PKC protein kinase C
PMSG pregnant mare serum gonadotropin
8-PTH 8-phenyltheophylline
RyR ryanodine receptor
SAM S-adenosylmethionine
SAH S-adenosylhomocysteine
SERCA Ca2+-ATPase
TME tumor microenvironment
UTP uridine triphosphate
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